The Apex Times
Above the Noise
Business Wire
BusinessEli Lilly’s reported $2.9B Merida acquisition sparks M&A chatter as SLS and IBRX rebound after AugustThe Apex TimesBusinessElon Musk’s chip preference spotlights Nvidia’s edge over AMD, but investors still watch executionThe Apex TimesBusinessTesla shares outpaced Rivian and Chinese EV rivals in August as Robotaxi rollout inched higher, traders looked ahead to the next Cybercab pushThe Apex TimesBusinessModerna shares surge 156% in August as investors bet on clinical progressThe Apex TimesBusinessMing-Chi Kuo says Nvidia has revived Rubin CPX after it seemingly vanished from the AI roadmapThe Apex TimesBusinessApple’s next CEO arrives with a different kind of power: money, and an AI testThe Apex TimesBusinessTesla and Einride set first 2026 delivery timeline for 500 Semi trucksThe Apex TimesBusinessZonPrep buys inbound-inventory software and services, betting on Amazon logistics automationThe Apex TimesBusinessNvidia pauses part of its AI customer financing after a strong quarter, raising questions about timingThe Apex TimesBusinessBoeing Teams With Thailand’s Civil Aviation Authority to Roll Out Competency-Based Pilot Training Across the CountryThe Apex TimesBusinessApple CEO transition hands AI test to John Ternus as AAPL slipsThe Apex TimesBusinessAnthropic reportedly signs $35 billion cloud deal involving Nvidia-backed Lambda and a Texas data-center leaseThe Apex TimesBusinessEli Lilly’s reported $2.9B Merida acquisition sparks M&A chatter as SLS and IBRX rebound after AugustThe Apex TimesBusinessElon Musk’s chip preference spotlights Nvidia’s edge over AMD, but investors still watch executionThe Apex TimesBusinessTesla shares outpaced Rivian and Chinese EV rivals in August as Robotaxi rollout inched higher, traders looked ahead to the next Cybercab pushThe Apex TimesBusinessModerna shares surge 156% in August as investors bet on clinical progressThe Apex TimesBusinessMing-Chi Kuo says Nvidia has revived Rubin CPX after it seemingly vanished from the AI roadmapThe Apex TimesBusinessApple’s next CEO arrives with a different kind of power: money, and an AI testThe Apex TimesBusinessTesla and Einride set first 2026 delivery timeline for 500 Semi trucksThe Apex TimesBusinessZonPrep buys inbound-inventory software and services, betting on Amazon logistics automationThe Apex TimesBusinessNvidia pauses part of its AI customer financing after a strong quarter, raising questions about timingThe Apex TimesBusinessBoeing Teams With Thailand’s Civil Aviation Authority to Roll Out Competency-Based Pilot Training Across the CountryThe Apex TimesBusinessApple CEO transition hands AI test to John Ternus as AAPL slipsThe Apex TimesBusinessAnthropic reportedly signs $35 billion cloud deal involving Nvidia-backed Lambda and a Texas data-center leaseThe Apex TimesBusinessEli Lilly’s reported $2.9B Merida acquisition sparks M&A chatter as SLS and IBRX rebound after AugustThe Apex TimesBusinessElon Musk’s chip preference spotlights Nvidia’s edge over AMD, but investors still watch executionThe Apex TimesBusinessTesla shares outpaced Rivian and Chinese EV rivals in August as Robotaxi rollout inched higher, traders looked ahead to the next Cybercab pushThe Apex TimesBusinessModerna shares surge 156% in August as investors bet on clinical progressThe Apex TimesBusinessMing-Chi Kuo says Nvidia has revived Rubin CPX after it seemingly vanished from the AI roadmapThe Apex TimesBusinessApple’s next CEO arrives with a different kind of power: money, and an AI testThe Apex TimesBusinessTesla and Einride set first 2026 delivery timeline for 500 Semi trucksThe Apex TimesBusinessZonPrep buys inbound-inventory software and services, betting on Amazon logistics automationThe Apex TimesBusinessNvidia pauses part of its AI customer financing after a strong quarter, raising questions about timingThe Apex TimesBusinessBoeing Teams With Thailand’s Civil Aviation Authority to Roll Out Competency-Based Pilot Training Across the CountryThe Apex TimesBusinessApple CEO transition hands AI test to John Ternus as AAPL slipsThe Apex TimesBusinessAnthropic reportedly signs $35 billion cloud deal involving Nvidia-backed Lambda and a Texas data-center leaseThe Apex TimesBusinessEli Lilly’s reported $2.9B Merida acquisition sparks M&A chatter as SLS and IBRX rebound after AugustThe Apex TimesBusinessElon Musk’s chip preference spotlights Nvidia’s edge over AMD, but investors still watch executionThe Apex TimesBusinessTesla shares outpaced Rivian and Chinese EV rivals in August as Robotaxi rollout inched higher, traders looked ahead to the next Cybercab pushThe Apex TimesBusinessModerna shares surge 156% in August as investors bet on clinical progressThe Apex TimesBusinessMing-Chi Kuo says Nvidia has revived Rubin CPX after it seemingly vanished from the AI roadmapThe Apex TimesBusinessApple’s next CEO arrives with a different kind of power: money, and an AI testThe Apex TimesBusinessTesla and Einride set first 2026 delivery timeline for 500 Semi trucksThe Apex TimesBusinessZonPrep buys inbound-inventory software and services, betting on Amazon logistics automationThe Apex TimesBusinessNvidia pauses part of its AI customer financing after a strong quarter, raising questions about timingThe Apex TimesBusinessBoeing Teams With Thailand’s Civil Aviation Authority to Roll Out Competency-Based Pilot Training Across the CountryThe Apex TimesBusinessApple CEO transition hands AI test to John Ternus as AAPL slipsThe Apex TimesBusinessAnthropic reportedly signs $35 billion cloud deal involving Nvidia-backed Lambda and a Texas data-center leaseThe Apex Times
Back to front
Jim Cramer highlighted Johnson & Johnson as its shares rose, as investors weighed a broader mixed tape
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jun 14, 3:24 PM EDT

Jim Cramer highlighted Johnson & Johnson as its shares rose, as investors weighed a broader mixed tape

A recent Yahoo Finance segment featuring Jim Cramer pointed to Johnson & Johnson’s (NYSE:JNJ) stock strength, noting the shares had gained roughly 5% ahead of the discussion.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Jim Cramer used Johnson & Johnson as an example of a healthcare name showing relative strength during a period when investors have been rotating across sectors, according to a Yahoo Finance post summarizing his remarks. The item states that Johnson & Johnson’s shares were up by about 5% and were among the stocks Cramer discussed.

The Yahoo Finance post frames the Johnson & Johnson mention as part of a wider set of 12 stocks that Cramer highlighted, while he also addressed other market themes tied to high-profile developments. In that context, JNJ appears less as the centerpiece of a detailed corporate update and more as a stock the TV host pointed to during a larger discussion.

Beyond the market framing, the Yahoo Finance item does not provide specific detail about what moved Johnson & Johnson shares on its own, nor does it describe any particular catalyst such as earnings results, regulatory actions, product approvals, or litigation updates. The post’s available summary focuses on the share-price change and the fact that the company was included in Cramer’s selected list.

The limited information also leaves open how investors interpreted the move. A gain of roughly 5% can reflect a range of forces, from broader risk appetite and sector flows to anticipation around upcoming company disclosures. The Yahoo Finance summary does not specify which driver, if any, was most responsible for the performance.

Johnson & Johnson operates in healthcare, a category many investors treat as a staple in portfolios because it spans areas tied to consumer health, hospital demand, and prescription medicines. Even so, without additional detail in the Yahoo Finance item, it is not possible to attribute JNJ’s move to any specific segment, product, or management action.

For now, the most actionable takeaway from the Yahoo Finance item is directional rather than fundamental: the stock’s recent strength is being spotlighted publicly in the media ecosystem. Investors watching the name may want to focus on whether the market’s interest is reinforced by forthcoming company communication, such as earnings, guidance updates, or regulatory and product announcements, rather than by television commentary alone.

As with many “stocks to watch” segments, the key limitation is what is not disclosed. The Yahoo Finance summary does not break down valuation, compare JNJ to peers, identify the precise reasons behind the share move, or provide any new company-specific information that would normally accompany an actionable thesis.

Why It Matters

  • Media spotlights like this can influence short-term retail and momentum interest, especially when framed around a clear percentage gain.
  • Because no specific operational catalyst is cited, the market may treat the move as continuation of broader trading dynamics rather than a confirmed fundamental change.
  • Investors may need to look for follow-through from company disclosures to determine whether the price action is durable.
  • The lack of detail underscores how quickly public commentary can diverge from what actually drives results in healthcare.

Sources

Key Facts

  • The Yahoo Finance post summarized Jim Cramer’s discussion of a set of 12 stocks that included Johnson & Johnson (NYSE:JNJ).
  • The summary states Johnson & Johnson shares had gained roughly 5% by the time of the discussion.
  • The item also referenced broader market themes, including Cramer’s commentary beyond JNJ, such as SpaceX’s IPO.
  • The available summary does not specify a company-specific catalyst (for example, earnings, approvals, or litigation updates).
  • The post does not provide valuation metrics or comparisons to other healthcare stocks.

Healthcare Related

Jim Cramer highlighted Johnson & Johnson as its shares rose, as investors weighed a broader mixed tape | The Apex Times